Clinical trials: Osimertinib
Advanced Solid Tumors Which Are cMET-dependent
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or…
- Trial name
- NCT03040973
- Testing
- Capmatinib, Nazartinib, Gefitinib
- Where
- 15 sites in United States, Belgium and 9 more
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
Evaluate the efficacy and safety of Anlotinib combined with Icotinib as the second-line treatment in stage IIIb-IV NSCLC patients with sensitive EGFR and T790M mutations.
- Trial name
- ALTN-03 (NCT04029350)
- Testing
- Anlotinib Combined With Osimertinib
- Where
- 4 sites in China
- Volunteers
- 53 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT05880706
- Testing
- BL-B01D1, Osimertinib Mesylate Tablets
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
NSCLC Stage IV, EGFR Activating Mutation
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
This study is an open-label, single-arm phase 2 trial to evaluate the efficacy and safety of stereotactic radiotherapy (SRT) for patients with oligo-residual NSCLC after 3rd generation EGFR-TKIs.
- Trial name
- NCT04764214
- Testing
- 3rd generation EGFR-TKI, Consolidative SRT
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fudan University
Stage IB-IIIA Non-small Cell Lung Carcinoma
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without…
- Trial name
- ADAURA (NCT02511106)
- Testing
- AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
- Where
- 238 sites in United States, Australia and 23 more
- Volunteers
- 682 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
The purpose of this study is to test the safety of combining the drugs osimertinib and bevacizumab at different dose levels. The investigators want to find out what effects, good and/or bad, taking osimertinib and bevacizumab has…
- Trial name
- NCT02803203
- Testing
- osimertinib, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Resectable Non-small Cell Lung Cancer
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
This clinical trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Limertinib Followed by Sintilimab and Chemotherapy in resectable Stage II-IIIB EGFR-Mutant NSCLC.
- Trial name
- NEO-LISI (NCT07038460)
- Testing
- Limertinib+sintilimab+chemotherapy, Limertinib+chemotherapy, surgery
- Where
- 6 sites in China
- Volunteers
- 134 people
- Sponsor
- Wen-zhao ZHONG
NSCLC (Advanced Non-small Cell Lung Cancer)
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
This study is an open, multicenter, phase II clinical study for evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ALK202 for injection combined with different drugs in participants with locally…
- Trial name
- NCT07603791
- Testing
- ALK202 for injection, Osimertinib Mesylate Tablets, Ivonescimab Injection
- Volunteers
- 252 people
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
Non-Small Cell Lung Cancer
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
This investigator-initiated study aims to evaluate the effectiveness of minimal residual disease (MRD) as a biomarker for guiding adjuvant therapy decisions in patients with Stage I non-small-cell lung cancer (NSCLC).
- Trial name
- MOTION-NSCLC (NCT06709274)
- Testing
- Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
- Where
- 15 sites in China
- Volunteers
- 342 people
- Sponsor
- Guangdong Association of Clinical Trials
Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in…
- Trial name
- UmbREALung (NCT06726720)
- Where
- 70 sites in France, Germany
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Trial name
- NCT07100080
- Testing
- Iza-bren, Carboplatin, Cisplatin
- Where
- 187 sites in United States, Argentina and 23 more
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer, CNS Progression
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
This trial is testing two novel combinations (temozolomide plus osimertinib OR temozolomide plus lorlatinib) which have not been evaluated in clinical trials. Thus, the exact benefits of these novel combinations are unclear.
- Trial name
- NCT04541407
- Testing
- Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
Non-Small Cell Lung Cancer, EGFR Mutation
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Protocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer The main purpose of this research study is to Find a safe…
- Conditions
- Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
- Trial name
- NCT07285148
- Testing
- ANS014004 + PLB1004, ANS014004 + Osimertinib
- Where
- United States
- Volunteers
- 253 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR…
- Trial name
- NCT05132777
- Testing
- JMT101, Osimertinib Mesylate Tablets
- Volunteers
- 155 people
- Sponsor
- Shanghai JMT-Bio Inc.
Carcinoma, Non-Small-Cell Lung
Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS
This is a local, prospective, non-interventional, regulatory postmarketing surveillance study. The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study…
- Trial name
- KOREA-PLUS (NCT03918304)
- Where
- 10 sites in South Korea
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Uncommon EGFR AZD9291
EGFR (ErbB1) mutations define a lung cancer subtype with exquisite sensitivity to EGFR tyrosine kinase inhibitors (TKIs). While in-frame deletion in exon 19 (Del19) and a point mutation (L858R) in exon 21 are the two most common…
- Trial name
- NCT03424759
- Testing
- AZD9291
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Samsung Medical Center
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC
This single-site, biomarker-enriched, randomized Phase II study will evaluate osimertinib with or without cyclosporine A (CsA) in metastatic epidermal growth factor receptor (EGFR )-mutant non-small cell lung cancer (NSCLC) [exon…
- Trial name
- OCEAN (NCT07874490)
- Testing
- Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Non Small Cell Lung Cancer
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
This is a research study to find out if a drug called, osimertinib, is safe and effective in treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal growth factor receptor (EGFR) mutation exon…
- Trial name
- NCT03434418
- Testing
- osimertinib
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Brain Tumor
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
This is a single center, multi-arm, biomarker-driven phase 1 study to assess the RP2D, PK/PD, safety, and activity of tepotinib in participants with MET alterations and brain tumors.
- Trial name
- NCT05120960
- Testing
- tepotinib, tepotinib plus osimertinib
- Sponsor
- M.D. Anderson Cancer Center